In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Agios nets $516mm through public offering

Executive Summary

Agios Pharmaceuticals Inc. (therapies for cancer and rare genetic diseases) netted $516mm through a public offering of 8.1mm common shares (including the overallotment) at $67. Proceeds will support the company's pipeline activities, including late-stage development, approval, and commercial launch of ivosidenib for acute myeloid leukemia and solid tumors, and planned trials with AG348 for PK deficiency and thalassemia.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies